Home Alzheimer’s Disease Previous Cancer Diagnoses Associated with Subsequent Development of Multiple Myeloma

Previous Cancer Diagnoses Associated with Subsequent Development of Multiple Myeloma

Previous Hodgkin lymphoma and primary myelofibrosis diagnoses were associated with a subsequent identification of multiple myeloma, while the overall incidence rates of previous cancers were not found to be increased for these patients, according to data published in the European Journal of Haematology.

“We demonstrate that the overall incidence of previous cancers in [patients with multiple myeloma] is not greater than in an age-matched control cohort,” wrote the investigators. “We found significant associations between Hodgkin lymphoma and primary myelofibrosis and the subsequent development of [multiple myeloma]. With regards to [second primary malignancies], the well-known increased risk for [acute myeloid leukemia/myelodysplastic syndrome (AML/MDS)] is further underlined by our study.”

To further specify, the data found diagnoses of Hodgkin lymphoma (odds ratio [OR], 3.66;…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments